< Previous
| Home
| Next >
AIDS Drug Assistance Program: Formulary
|
Performance Measure:
ADAP: Eligibility Recertification TOP
Related OPR Measure: No |
Percentage of new anti-retroviral classes that are included in the ADAP formulary
within 90 days of the date of inclusion of new anti-retroviral classes in the PHS
Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and
Adolescents [ 1 ] during the measurement year.
Number of new anti-retroviral classes included into the ADAP formulary within 90 days
of the publication of updated PHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected
Adults and Adolescents that include new anti-retroviral drug class during the
measurement year.
Total number of new antiretroviral classes published in updated PHS Guidelines during
the measurement year.
-
PHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and
Adolescents published in the last ninety days of the measurement year.
-
Did the updated PHS Guidelines for the Use of Antiretroviral Agents in HIV-1-
infected Adults and Adolescents include any new anti-retroviral classes? (Y/N)
-
If yes, (for each new class) was the new class included into the ADAP
formulary within 90 days of publication of updated PHS Guidelines for
the Use of Antiretroviral Agents in HIV-1-infected Adults and
Adolescents? (Y/N)
-
If yes, list the date of publication of PHS Guidelines for the Use
of Antiretroviral Agents in HIV-1-infected Adults and
Adolescents and date of inclusion in the ADAP formulary.
-
ADAP quarterly report
-
ADAP formulary
|
National Goals, Targets, or Benchmarks for Comparison TOP |
100% (Measure is a statutory requirement.)
The Ryan White HIV Treatment Modernization Act of 2006 (P.L. 109-415) [ 2 ]
mandates that the state-operated ADAP programs “shall ensure that the therapeutics included on the list of
classes of core antiretroviral therapeutics established by the Secretary under subsection (e) are, at a
minimum, the treatments provided by the State pursuant to this section”. HRSA/HAB has notified Part B
grantees of that all ADAPs must include agents from each of the core antiretroviral classes listed in PHS
Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents.[ 3 ]
These legislative and policy requirements have been specified in the Part B ADAP Grant Application.[ 4 ]
|
US Public Health Service Guidelines TOP |
US Public Health Service Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and
Adolescents [ 1 ] contains the list of classes of core antiretroviral therapeutics to be included in ADAP
formularies.
[1] Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents
in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008; 1-128. Download in
printer-friendly format (pdf 1.7MB)
[2] The Ryan White HIV Treatment Modernization Act of 2006 (P.L. 109-415), Section 202(a).
[3] HRSA/HAB, Policy Notice-07-03, "The Use of Ryan White HIV/AIDS Program, Part B (formerly Title II),
AIDS Drug Assistance Program (ADAP) Funds for Access, Adherence and Monitoring Services", September 2007.
[4] Program Guidance: HIV Care Grant Program Part B: States/Territories Formula and Supplemental Awards
and AIDS Drug Assistance Program Formula and Supplemental Awards, HRSA Announcement Numbers:
HRSA 08-091.
|